Monopar Therapeutics (MNPR)

• Market cap: $369M
• 1 day: -5.9%
• 5 days: -8.53%
• 1 month: -0.36%
• 3 months: -22.15%
• 6 months: -13.27%
• Year to date: -16.36%
• 1 year: 23.4%
• 5 years: 63.34%
• 10 years: -58.33%
• Sector: Healthcare
• Industry: Biotechnology

About: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Employees: 16